Novophage, a Boston, MA-based early-stage technology company that develops a new class of biologics for different industrial applications, has completed a $5.7m Series A round of financing.
The round was led by Flybridge Capital Partners, with participation from Founder Collective, Boston University (BU) and strategic investors Chevron Technology Ventures and The Kraft Group.
In conjunction with the funding, Micah Rosenbloom, co-founder of Brontes Technologies, has joined the company as CEO; Jon Karlen, a General Partner at Flybridge Capital Partners, joins the Board of Directors; Vinit Nijhawan, Managing Director of the Office of Technology Development at BU, joins the Board as an Observer.
Founded in 2007, Novophage develops and market synthetic biology-enabled products, which are designed to tackle the problems of bacterial contamination in industries such as oil and gas, pulp and paper and HVAC systems, to improve productivity and the overall environmental impact of these water-intensive industries.
The company’s founding team include Jim Collins, Ph.D., Chairman, Scientific Advisory Board; Dr. Timothy Lu, M.D., Ph.D., Scientific Founder and Director; Dr. Michael Koeris, Ph.D., President and COO; Dr. Brett Chevalier, Ph.D., Chief Scientific Officer.